 | |
 | |
| 臨床資料 | |
|---|---|
| AHFS/Drugs.com | Monograph |
| 懷孕分級 |
|
| 给药途径 | 鼻腔內吸入，局部塗搽 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物利用度 | 0.51% (鼻腔內) |
| 血漿蛋白結合率 | 91% |
| 药物代谢 | 鼻腔內 肝臟(CYP3A4-中介) |
| 生物半衰期 | 10小時 |
| 排泄途徑 | 腎臟 |
| 识别信息 | |
| |
| CAS号 |
80474-14-2（（丙酸酯））  90566-53-3
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C22H27F3O4S |
| 摩尔质量 | 444.508 g/mol |
| 3D模型（JSmol） | |
| |
| |
氟替卡松（英語：fluticasone）為一種綜合的糖皮质激素。
與糠酸酯（furoate）或丙酸酯（propanoate)的合成品可以用為局部抗炎性、比如鼻炎方面：
參見
註釋
參考文獻
- Jarvis B., Faulds D. (1999): Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs, 57(5), 769–803. PMID 10353302
- Johnson M. (1995): The anti-inflammatory profile of fluticasone propionate. Allergy, 50(23), 11–14. PMID 7604948
- Keating G.M., McCormack P.L. (2007): Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs, 67(16), 2383–2405. PMID 17983257
- Reynolds N.A., Lyseng-Williamson K.A., Wiseman L.R. (2005): Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 65(12), 1715–1734. PMID 16060707
- Spencer C.M., Jarvis B. (1999): Salmeterol/fluticasone propionate combination. Drugs, 57(6), 933–940. PMID 10400406
- Staresinic A.G., Sorkness C.A. (2000): Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Expert Opin Pharmacother, 1(6), 1227-1244. PMID 11249490
- Avamys, Zusammenfasuung der Merkmale des Arzneimittels (PDF; 440 kB), Stand Dezember 2012, Europäische Arzneimittelagentur.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||
